2.	Related Party

Based on its stock ownership in the Company, MD Anderson Cancer Center meets the criteria to be deemed a related party of Bio-Path Holdings. For the quarters ending June 30, 2013 and 2012, MD Anderson related party research and development expense was $32,067 and $367,588, respectively. MD Anderson related party research and development expense for the quarter ending June 30, 2013 was comprised of MD Anderson clinical trial hospital expense of $22,050 and $10,017 in technology license patent maintenance fees. As of June 30, 2013 accounts payable related party was $10,017 for patent maintenance fees, accrued expense related party was $37,050 for MD Anderson clinical trial hospital expense (See Notes 4., 5. and 6.), and accrued license payments related party of $50,000 for past patent expenses. As of June 30, 2012, the Company had $367,588 in research and development expense related party expense comprised of $345,000 for technology license impairment expense (See Note 1.) and $22,588 for siRNA patent expense.